Precision BioSciences, Inc. (DTIL)

NASDAQ: DTIL · IEX Real-Time Price · USD
1.19
+0.02 (1.71%)
Feb 2, 2023, 10:03 AM EST - Market open
1.71%
Market Cap 131.04M
Revenue (ttm) 20.84M
Net Income (ttm) -105.44M
Shares Out 110.96M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 162,139
Open 1.21
Previous Close 1.17
Day's Range 1.19 - 1.22
52-Week Range 0.95 - 5.20
Beta 1.47
Analysts Buy
Price Target 6.46 (+442.86%)
Earnings Date Mar 21, 2023

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblast... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 28, 2019
Employees 194
Stock Exchange NASDAQ
Ticker Symbol DTIL
Full Company Profile

Financial Performance

In 2021, DTIL's revenue was $115.53 million, an increase of 375.72% compared to the previous year's $24.29 million. Losses were -$30.60 million, -71.93% less than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for DTIL stock is "Buy." The 12-month stock price forecast is $6.46, which is an increase of 442.86% from the latest price.

Price Target
$6.46
(442.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today ...

3 weeks ago - Business Wire

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company's Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today ...

3 weeks ago - Business Wire

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today ...

1 month ago - Business Wire

iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases

PHILADELPHIA--(BUSINESS WIRE)-- iECURE , a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver diso...

2 months ago - Business Wire

Precision BioSciences Announces Change to its Board of Directors

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, ...

2 months ago - Business Wire

Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto...

3 months ago - Zacks Investment Research

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene edit...

4 months ago - Business Wire

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, tod...

4 months ago - Business Wire

Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, tod...

5 months ago - Business Wire

Precision BioSciences Announces Senior Leadership Organizational Changes

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene edit...

5 months ago - Business Wire

Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, to...

6 months ago - Business Wire

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, to...

6 months ago - Business Wire

All You Need to Know About Precision BioSciences (DTIL) Rating Upgrade to Strong Buy

Precision BioSciences (DTIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

6 months ago - Zacks Investment Research

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editin...

7 months ago - Business Wire

Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

7 months ago - Zacks Investment Research

Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal

DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novar...

Other symbols: NVS
8 months ago - InvestorPlace

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ: DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE: NVS)  Precisi...

8 months ago - Benzinga

Precision BioSciences Announces $50 Million Offering of Common Stock

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, tod...

8 months ago - Business Wire

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editi...

8 months ago - Business Wire